NEW YORK (GenomeWeb News) – The European Union has funded a new €6 million ($8 million) project led by the Charité - Universitätsmedizin Berlin, the medical school for Humboldt University and the Free University of Berlin, that seeks to develop new biomarker tests for tailoring treatments for breast cancer patients.
The project, called RESPONSIFY, aims to develop tests to indicate how therapies will affect individual patients and enable doctors to make better decisions about whether to use neoadjuvant therapies or provide treatments after surgery.
The three-year project will include partners in Belgium, France, Germany, Sweden, Switzerland, and the UK, the European Commission said this week.
The partners will use a range of genome-based approaches, including genome-wide next-generation sequencing, epigenetics, gene and exon expression analysis, in situ proteomics, and quantitative PCR, to identify and characterize new biomarkers and to validate markers from earlier projects.
The results from the project will be presented on a web-based data integration and processing system that will provide easy access to the information for future clinical biomarker trials.
"The advantage of neoadjuvant therapy is that the effective response of the therapy on the tumor is immediately visible. This is why we are better able to judge which biomarkers are appropriate for directing the therapy," Carsten Denkert, project director at the Charité Institute of Pathology, said in a statement.